WHO Moves Into Prequalification Of Biosimilars; Two Anticancers First In Line

The World Health Organization is to pilot the prequalification of biosimilars in a bid to make expensive cancer treatments more widely available to patients. Ritixumab and trastuzumab will be first in line. The EU generics and biosimilars industry has welcomed the initiative, saying the introduction of biosimilars in the field of oncology could lead to significant changes to standards of care for patients.